A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
By S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, P. Richardson, R. Niesvizky, R. Alexanian, S. Limentani, M. Alsina and 5 more. British Journal of Haematology, 2004
758 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/7dc8adc51ead8fa64e27e751ed3a66a683f44978
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006, result): “The safety profile of bortezomib was predictable and manageable, and similar to that in relapsed or refractory MM.(50-52) The incidence of peripheral neuropathy was higher compared with the Assessment of Proteasome Inhibition for Extending Remissions phase III study in MM,(51) perhaps due to inheren”
- Targeting Apoptosis Pathways in Cancer Therapy (2005, background): “The success of this trial led to the accelerated FDA approval of bortezomib in patients with relapsed or refractory multiple myeloma.(100,101) Toxicities include lowgrade fever, fatigue, thrombocytopenia, peripheral neuropathy, and low-grade diarrhea.”
- Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. (2006, methodology): “The eligibility criteria for the patients enrolled onto SUMMIT and CREST have been described previously.(1,2) Eligible patients had relapsed and/or refractory myeloma; patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS) were excluded, ”